Dysregulation of Gene Expression in Primary Neuron Models of Huntington's Disease Shows That Polyglutamine-Related Effects on the Striatal Transcriptome May Not Be Dependent on Brain Circuitry

Gene expression changes are a hallmark of the neuropathology of Huntington's disease (HD), but the exact molecular mechanisms of this effect remain uncertain. Here, we report that in vitro models of disease comprised of primary striatal neurons expressing N-terminal fragments of mutant huntingtin (via lentiviral gene delivery) faithfully reproduce the gene expression changes seen in human HD. Neither viral infection nor unrelated (enhanced green fluorescent protein) transgene expression had a major effect on resultant RNA profiles. Expression of a wild-type fragment of huntingtin [htt171-18Q] also caused only a small number of RNA changes. The disease-related signal in htt171-82Q versus htt171-18Q comparisons was far greater, resulting in the differential detection of 20% of all mRNA probe sets. Transcriptomic effects of mutated htt171 are time- and polyglutamine-length dependent and occur in parallel with other manifestations of polyglutamine toxicity over 4–8 weeks. Specific RNA changes in htt171-82Q-expressing striatal cells accurately recapitulated those observed in human HD caudate and included decreases in PENK (proenkephalin), RGS4 (regulator of G-protein signaling 4), dopamine D1 receptor (DRD1), DRD2, CNR1 (cannabinoid CB1 receptor), and DARPP-32 (dopamine- and cAMP-regulated phosphoprotein-32; also known as PPP1R1B) mRNAs. HD-related transcriptomic changes were also observed in primary neurons expressing a longer fragment of mutant huntingtin (htt853-82Q). The gene expression changes observed in cultured striatal neurons are not secondary to abnormalities of neuronal firing or glutamatergic, dopaminergic, or brain-derived neurotrophic factor signaling, thereby demonstrating that HD-induced dysregulation of the striatal transcriptome might be attributed to intrinsic effects of mutant huntingtin.

[1]  P. Holmans,et al.  Brain gene expression correlates with changes in behavior in the R6/1 mouse model of Huntington’s disease , 2008, Genes, brain, and behavior.

[2]  Regina M Murphy,et al.  Reconsidering the mechanism of polyglutamine peptide aggregation. , 2007, Biochemistry.

[3]  Emmanuel Brouillet,et al.  Progressive and selective striatal degeneration in primary neuronal cultures using lentiviral vector coding for a mutant huntingtin fragment , 2005, Neurobiology of Disease.

[4]  Joseph B. Martin.  Huntington's disease , 1984, Neurology.

[5]  I. Módy,et al.  Pathological Cell-Cell Interactions Elicited by a Neuropathogenic Form of Mutant Huntingtin Contribute to Cortical Pathogenesis in HD Mice , 2005, Neuron.

[6]  Fabrice P Cordelières,et al.  Huntingtin Controls Neurotrophic Support and Survival of Neurons by Enhancing BDNF Vesicular Transport along Microtubules , 2004, Cell.

[7]  R. Luthi-Carter.  Huntington's and other polyglutamine diseases: many effects of single gene mutations , 2007 .

[8]  J. M. Boutell,et al.  Aberrant interactions of transcriptional repressor proteins with the Huntington's disease gene product, huntingtin. , 1999, Human molecular genetics.

[9]  C. Mariotti,et al.  Progressive dysfunction of the cholesterol biosynthesis pathway in the R6/2 mouse model of Huntington’s disease , 2007, Neurobiology of Disease.

[10]  Charles Kooperberg,et al.  Dysregulation of gene expression in the R6/2 model of polyglutamine disease: parallel changes in muscle and brain. , 2002, Human molecular genetics.

[11]  J. Olson,et al.  Regional and cellular gene expression changes in human Huntington's disease brain. , 2006, Human molecular genetics.

[12]  James R. Burke,et al.  Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines , 2002, Nature Neuroscience.

[13]  Xi Chen,et al.  Dopaminergic Signaling and Striatal Neurodegeneration in Huntington's Disease , 2007, The Journal of Neuroscience.

[14]  Mauro Delorenzi,et al.  Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood , 2007, Proceedings of the National Academy of Sciences.

[15]  R. Llinás,et al.  Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[16]  C. Cepeda,et al.  Pathological cell-cell interactions are necessary for striatal pathogenesis in a conditional mouse model of Huntington's disease , 2007, Molecular Neurodegeneration.

[17]  D. Housman,et al.  Insoluble detergent-resistant aggregates form between pathological and nonpathological lengths of polyglutamine in mammalian cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[18]  J. Cha,et al.  Mechanisms of transcriptional dysregulation in Huntington's disease , 2003, Clinical Neuroscience Research.

[19]  L. Farrell,et al.  Mutant huntingtin increases nuclear corepressor function and enhances ligand-dependent nuclear hormone receptor activation , 2003, Molecular and Cellular Neuroscience.

[20]  M. MacDonald,et al.  Huntingtin's WW domain partners in Huntington's disease post-mortem brain fulfill genetic criteria for direct involvement in Huntington's disease pathogenesis. , 2000, Human molecular genetics.

[21]  J. Rothman,et al.  Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway , 2006, The Journal of cell biology.

[22]  S. Snyder,et al.  p53 Mediates Cellular Dysfunction and Behavioral Abnormalities in Huntington’s Disease , 2005, Neuron.

[23]  Jacki Y. Brown,et al.  Aberrant cortical synaptic plasticity and dopaminergic dysfunction in a mouse model of Huntington's disease. , 2006, Human molecular genetics.

[24]  Ruth Luthi-Carter,et al.  Cross-species and cross-platform gene expression studies with the Bioconductor-compliant R package 'annotationTools' , 2008, BMC Bioinformatics.

[25]  R. Wightman,et al.  Dopamine release is severely compromised in the R6/2 mouse model of Huntington's disease , 2006, Journal of neurochemistry.

[26]  M. MacDonald,et al.  RESEARCH ARTICLE: Systematic Assessment of BDNF and Its Receptor Levels in Human Cortices Affected by Huntington's Disease , 2007, Brain pathology.

[27]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[28]  R. Ferrante,et al.  ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease , 2006, Proceedings of the National Academy of Sciences.

[29]  D. Housman,et al.  Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila , 2001, Nature.

[30]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[31]  F. Walker.  Huntington's disease , 2007, The Lancet.

[32]  L. Raymond,et al.  Increased Sensitivity to N-Methyl-D-Aspartate Receptor-Mediated Excitotoxicity in a Mouse Model of Huntington's Disease , 2002, Neuron.

[33]  Jaclyn I. Wamsteeker,et al.  Increased metabolism in the R6/2 mouse model of Huntington’s disease , 2008, Neurobiology of Disease.

[34]  J. Olson,et al.  Expression Profiling of Huntington's Disease Models Suggests That Brain-Derived Neurotrophic Factor Depletion Plays a Major Role in Striatal Degeneration , 2007, The Journal of Neuroscience.

[35]  R. Ferrante,et al.  Modulation of nucleosome dynamics in Huntington's disease. , 2007, Human molecular genetics.

[36]  Katalin Illes,et al.  Mutant huntingtin alters MAPK signaling pathways in PC12 and striatal cells: ERK1/2 protects against mutant huntingtin-associated toxicity. , 2006, Human molecular genetics.

[37]  S. Luquet,et al.  Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. , 2006, Cell metabolism.

[38]  Dimitri Krainc,et al.  Sp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease , 2002, Science.

[39]  S. Dunnett,et al.  Pharmaceutical, cellular and genetic therapies for Huntington's disease. , 2006, Clinical science.

[40]  J. Bloch,et al.  Expression of mutated huntingtin fragment in the putamen is sufficient to produce abnormal movement in non-human primates. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[41]  G. Bates,et al.  Huntingtin and the molecular pathogenesis of Huntington's disease , 2004, EMBO reports.

[42]  Y. Benjamini,et al.  Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .

[43]  Andrea Crotti,et al.  Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes , 2003, Nature Genetics.

[44]  L. Tora,et al.  Transcriptional alterations and chromatin remodeling in polyglutamine diseases. , 2006, Trends in genetics : TIG.

[45]  Mauro Delorenzi,et al.  Mutant huntingtin's effects on striatal gene expression in mice recapitulate changes observed in human Huntington's disease brain and do not differ with mutant huntingtin length or wild-type huntingtin dosage. , 2007, Human molecular genetics.

[46]  W. Low,et al.  Age‐Dependent Changes in the Calcium Sensitivity of Striatal Mitochondria in Mouse Models of Huntington's Disease , 2005, Journal of neurochemistry.

[47]  Carlos Cepeda,et al.  Transient and Progressive Electrophysiological Alterations in the Corticostriatal Pathway in a Mouse Model of Huntington's Disease , 2003, The Journal of Neuroscience.